Home >> Healthcare >> Psoriasis Biosimilar Market

Global Psoriasis Biosimilar Market Size,Trends, Growth Forecast to 2031

Category : Healthcare | Report Code : 1068 | Pages : 141 | Oct 2024

Report Overview

A psoriasis biosimilar refers to a biologic drug that is highly similar to an existing FDA-approved biologic treatment (the reference product) used for treating psoriasis, a chronic autoimmune condition that causes rapid skin cell turnover, leading to scales and inflamed patches of skin. Biosimilars are developed after the original biologic's patent expires and are designed to be equally effective, safe, and of the same high quality as the original.

The global Psoriasis Biosimilar market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

Analytic Insights Hub ' newest research report, the “Psoriasis Biosimilar Industry Forecast” looks at past sales and reviews total world Psoriasis Biosimilar sales in 2023, providing a comprehensive analysis by region and market sector of projected Psoriasis Biosimilar sales for 2024 through 2030. With Psoriasis Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psoriasis Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Psoriasis Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psoriasis Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psoriasis Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psoriasis Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psoriasis Biosimilar.

United States market for Psoriasis Biosimilar is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Psoriasis Biosimilar is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Psoriasis Biosimilar is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Psoriasis Biosimilar players cover Merck KGaA, Gyros Protein Technologies AB, Pfizer Inc., Novartis International AG, Amgen Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly 
 % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Psoriasis Biosimilar market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
    Other Biosimilars

Segmentation by Application:
    Plaque Psoriasis
    Psoriatic Arthritis
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    Merck KGaA
    Gyros Protein Technologies AB
    Pfizer Inc.
    Novartis International AG
    Amgen Inc
    Samsung Bioepis Co., Ltd.
    Coherus BioSciences
    Hoffmann-La Roche Ltd
    Celltrion
    Samsung Bioepis
    Sandoz
    Fresenius Kabi
    Viatris
    Reddy's Laboratories
    GenScript

Key Questions Addressed in this Report
What is the 10-year outlook for the global Psoriasis Biosimilar market?
What factors are driving Psoriasis Biosimilar market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psoriasis Biosimilar market opportunities vary by end market size?
How does Psoriasis Biosimilar break out by Type, by Application?

Frequently Asked Questions?

Ans - The purpose of a Psoriasis Biosimilar market research report is to provide data-driven insights and analysis on a Psoriasis Biosimilar market. It helps businesses understand industry trends, competition, consumer behavior, market size, growth potential, and risks, supporting strategic decision-making.

Ans - Market research reports typically include both quantitative (market size, revenue, growth rates) and qualitative (trends, consumer preferences, competitive analysis) data. It often includes industry statistics, surveys, expert opinions, historical data, and future forecasts.

Ans - The forecast period typically for Psoriasis Biosimilar market report spans the next 5 to 10 years. It includes projected market trends, growth opportunities, and potential challenges.

Ans - Yes, Analytic Insights Hub customization services, allowing businesses to focus on specific geographies, sectors, or market segments that are relevant to them.

Ans - The report highlights major trends such as technological innovations, consumer behavior shifts, regulatory changes, or emerging markets that may impact the industry?s growth.